Vincristine
Information
- Drug Name
- Vincristine
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| malignant astrocytoma |
ATRX UNDEREXPRESSION ( ENST00000373344.11 ) ATRX UNDEREXPRESSION ( ENST00000373344.11 ) |
B |
Predictive
|
Supports
|
N/A
|
3 | 23904111 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A retrospective tumor sample study found that the ... | ATRX |
ATRX UNDEREXPRESSION ( ENST00000373344.11 ) ATRX UNDEREXPRESSION ( ENST00000373344.11 ) |
N/A | true | CIViC Evidence | detail |
| CP-31398 can stabilize wild-type p53 and rescue mu... | TP53 | TP53 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| XBP-1 (an ER stress response protein) activates AK... | XBP1 | XBP1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Results were based on both expression and inhibiti... | GSTM1 | GSTM1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Uveal melanoma | ABCB1 | ABCB1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Uveal melanoma | ABCC1 | ABCC1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03467373 | Active, not recruiting | Phase 1 | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | March 13, 2018 | October 30, 2024 |
| NCT03274492 | Active, not recruiting | Phase 3 | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | November 16, 2017 | June 27, 2024 |
| NCT00092222 | Active, not recruiting | Phase 2 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | October 28, 2004 | October 1, 2025 |
| NCT02752815 | Active, not recruiting | Phase 4 | Reduced Chemotherapy in Low Risk DLBCL | June 14, 2016 | December 31, 2024 |
| NCT02724579 | Active, not recruiting | Phase 2 | Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma | November 17, 2017 | June 30, 2027 |
| NCT03817320 | Active, not recruiting | Phase 1/Phase 2 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | February 12, 2019 | June 30, 2025 |
| NCT03808610 | Active, not recruiting | Phase 1/Phase 2 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | April 3, 2019 | December 31, 2026 |
| NCT00878254 | Active, not recruiting | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | March 25, 2009 | September 2027 |
| NCT03792256 | Active, not recruiting | Phase 1 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | April 11, 2019 | June 30, 2025 |
| NCT03407144 | Active, not recruiting | Phase 2 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | April 9, 2018 | February 13, 2027 |
| NCT04517435 | Active, not recruiting | Phase 1/Phase 2 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | April 28, 2021 | July 2025 |
| NCT01424982 | Active, not recruiting | Phase 2 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | October 5, 2011 | October 31, 2025 |
| NCT03147612 | Active, not recruiting | Phase 2 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | February 8, 2018 | February 28, 2025 |
| NCT03786783 | Active, not recruiting | Phase 2 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | March 4, 2019 | September 22, 2024 |
| NCT02661503 | Active, not recruiting | Phase 3 | HD21 for Advanced Stages | July 2016 | September 2025 |
| NCT01464606 | Active, not recruiting | N/A | International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry | December 22, 2009 | December 2024 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT04214626 | Active, not recruiting | Phase 2 | R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma | January 2, 2020 | January 2, 2025 |
| NCT02303821 | Active, not recruiting | Phase 1 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | February 16, 2015 | July 14, 2024 |
| NCT03020030 | Active, not recruiting | Phase 3 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | March 3, 2017 | November 2034 |
| NCT04914741 | Active, not recruiting | Phase 1/Phase 2 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | June 29, 2021 | July 2025 |
| NCT00136435 | Active, not recruiting | Phase 2 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | June 2002 | July 2024 |
| NCT05201248 | Active, not recruiting | Phase 1 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | March 10, 2022 | December 13, 2024 |
| NCT02553460 | Active, not recruiting | Phase 1/Phase 2 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | January 29, 2016 | October 2031 |
| NCT00006721 | Active, not recruiting | Phase 3 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | March 2001 | March 2024 |
| NCT03017326 | Active, not recruiting | Phase 3 | Paediatric Hepatic International Tumour Trial | August 24, 2017 | August 1, 2027 |
| NCT04824092 | Active, not recruiting | Phase 3 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | May 11, 2021 | May 2026 |
| NCT02427620 | Active, not recruiting | Phase 2 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | June 3, 2015 | June 30, 2025 |
| NCT03589326 | Active, not recruiting | Phase 3 | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | October 4, 2018 | July 31, 2027 |
| NCT01096368 | Active, not recruiting | Phase 3 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | May 7, 2010 | September 22, 2024 |
| NCT02143414 | Active, not recruiting | Phase 2 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | June 30, 2015 | October 23, 2024 |
| NCT01783535 | Active, not recruiting | Phase 2 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | June 19, 2013 | January 2028 |
| NCT02911142 | Active, not recruiting | Phase 1/Phase 2 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | July 3, 2017 | October 1, 2027 |
| NCT05008224 | Active, not recruiting | Phase 2 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | October 7, 2021 | May 22, 2024 |
| NCT00476190 | Active, not recruiting | Phase 2 | ALL Adult Consortium Trial: Adult ALL Trial | April 2007 | December 2024 |
| NCT01857934 | Active, not recruiting | Phase 2 | Therapy for Children With Advanced Stage Neuroblastoma | July 5, 2013 | December 2024 |
| NCT01864109 | Active, not recruiting | Phase 2 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | May 2013 | May 2027 |
| NCT01871766 | Active, not recruiting | Phase 2 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | December 4, 2013 | June 2030 |
| NCT01878617 | Active, not recruiting | Phase 2 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | June 23, 2013 | January 2028 |
| NCT02889523 | Active, not recruiting | Phase 1/Phase 2 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | October 2016 | April 2026 |
| NCT02881086 | Active, not recruiting | Phase 3 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | August 2016 | July 2025 |
| NCT01920737 | Active, not recruiting | Phase 2 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | August 2013 | August 2024 |
| NCT05192889 | Active, not recruiting | Phase 1/Phase 2 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | August 25, 2022 | July 2029 |
| NCT01946529 | Active, not recruiting | Phase 2 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | December 27, 2013 | July 2026 |
| NCT02828358 | Active, not recruiting | Phase 2 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | April 1, 2017 | September 22, 2024 |
| NCT02003222 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | May 19, 2014 | December 4, 2024 |
| NCT04980222 | Active, not recruiting | Phase 2 | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | March 22, 2022 | June 1, 2025 |
| NCT03962465 | Active, not recruiting | Phase 1 | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL | July 22, 2022 | July 2026 |
| NCT04529772 | Active, not recruiting | Phase 3 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | October 8, 2020 | February 5, 2027 |
| NCT02101853 | Active, not recruiting | Phase 3 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | December 17, 2014 | September 22, 2024 |
| NCT02306161 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | December 12, 2014 | September 22, 2024 |
| NCT02112916 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | October 4, 2014 | September 22, 2024 |
| NCT02114229 | Active, not recruiting | Phase 2 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors | May 14, 2014 | September 2027 |
| NCT03677141 | Completed | Phase 1/Phase 2 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | March 8, 2019 | October 12, 2023 |
| NCT00450801 | Completed | Phase 2 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | April 2004 | July 2015 |
| NCT00451178 | Completed | Phase 2 | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | May 2007 | January 2013 |
| NCT00477412 | Completed | Phase 1/Phase 2 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | April 3, 2007 | October 28, 2020 |
| NCT03536039 | Completed | Phase 2 | RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | January 27, 2016 | January 27, 2020 |
| NCT00494780 | Completed | Phase 2 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | June 2007 | September 2010 |
| NCT00494897 | Completed | Phase 4 | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | June 1996 | December 2007 |
| NCT00526175 | Completed | Phase 4 | LAL-BR/2001: Study Treatment to Low Risk ALL | June 2001 | December 2015 |
| NCT00526305 | Completed | Phase 4 | LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | January 2000 | April 2005 |
| NCT00526409 | Completed | Phase 4 | LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia | June 2005 | October 2014 |
| NCT00537550 | Completed | N/A | Adult ALL Treatment at Diagnosis | July 2000 | June 2006 |
| NCT00556127 | Completed | Phase 2 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | June 2002 | September 2006 |
| NCT03384654 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | May 14, 2018 | September 27, 2022 |
| NCT00577993 | Completed | Phase 3 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | March 16, 1998 | August 24, 2017 |
| NCT00581776 | Completed | Phase 2 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | May 2005 | May 2015 |
| NCT00613457 | Completed | Phase 3 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | September 2000 | July 2006 |
| NCT03349281 | Completed | Phase 1 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | March 25, 2019 | October 12, 2022 |
| NCT00634179 | Completed | Phase 1/Phase 2 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | February 2008 | November 2015 |
| NCT00651755 | Completed | N/A | Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients | March 2008 | September 2011 |
| NCT00669877 | Completed | Phase 2 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | August 2002 | October 2015 |
| NCT00671658 | Completed | Phase 2 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | November 2002 | July 2013 |
| NCT00718757 | Completed | Phase 1 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | January 2005 | January 2009 |
| NCT00763763 | Completed | Phase 2 | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive | December 2004 | January 2010 |
| NCT00770224 | Completed | Phase 2 | S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | April 2009 | August 2019 |
| NCT00786669 | Completed | Phase 1 | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | October 2008 | November 2012 |
| NCT00787527 | Completed | Phase 1/Phase 2 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | November 2008 | December 2012 |
| NCT00801281 | Completed | Phase 3 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | February 2007 | June 25, 2017 |
| NCT03283202 | Completed | Phase 1 | Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors | October 4, 2017 | December 16, 2020 |
| NCT00825149 | Completed | Phase 1 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma | February 2009 | November 2015 |
| NCT00853008 | Completed | Phase 4 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia | January 2003 | December 2012 |
| NCT00866749 | Completed | Phase 2 | Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma | September 12, 2006 | July 26, 2018 |
| NCT00877006 | Completed | Phase 3 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | April 30, 2009 | March 31, 2012 |
| NCT03229746 | Completed | Phase 4 | Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia | August 1, 2017 | June 1, 2018 |
| NCT00890656 | Completed | Phase 2 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | June 2003 | January 2011 |
| NCT00905034 | Completed | Phase 2 | Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage | March 2009 | February 2015 |
| NCT00931918 | Completed | Phase 2 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | October 2009 | August 2015 |
| NCT00968253 | Completed | Phase 1/Phase 2 | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | November 2009 | December 2015 |
| NCT00973752 | Completed | Phase 2 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | August 2009 | April 2016 |
| NCT00993044 | Completed | Phase 1 | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | September 2009 | February 2013 |
| NCT01000285 | Completed | Phase 1/Phase 2 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma | September 2010 | April 2016 |
| NCT01004497 | Completed | Phase 2 | First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | March 2010 | April 2015 |
| NCT01004991 | Completed | Phase 1/Phase 2 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | January 2010 | February 2016 |
| NCT03003520 | Completed | Phase 2 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | February 28, 2017 | April 24, 2022 |
| NCT01040871 | Completed | Phase 2 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | January 2010 | August 2012 |
| NCT01148446 | Completed | Phase 3 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | January 2003 | |
| NCT01200758 | Completed | Phase 3 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | February 15, 2011 | October 31, 2017 |
| NCT01251107 | Completed | Phase 3 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | March 2000 | November 2009 |
| NCT01309789 | Completed | Phase 1 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | February 2011 | February 28, 2017 |
| NCT02809573 | Completed | Phase 1 | Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | August 11, 2016 | January 8, 2019 |
| NCT01324180 | Completed | Phase 1 | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | July 18, 2011 | July 27, 2017 |
| NCT01332968 | Completed | Phase 3 | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | July 6, 2011 | July 30, 2021 |
| NCT01336933 | Completed | Phase 2 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | July 6, 2011 | December 28, 2016 |
| NCT02786719 | Completed | N/A | High-Risk Neuroblastoma Chemotherapy Without G-CSF | June 2016 | February 5, 2019 |
| NCT01358253 | Completed | Phase 4 | Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia | December 2010 | December 2012 |
| NCT02684058 | Completed | Phase 2 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | December 28, 2017 | April 28, 2023 |
| NCT02677116 | Completed | Phase 1 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | August 29, 2016 | April 3, 2019 |
| NCT01397825 | Completed | Phase 1/Phase 2 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | August 9, 2011 | October 5, 2016 |
| NCT01399372 | Completed | Phase 2 | Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | September 2011 | May 20, 2022 |
| NCT01414855 | Completed | Phase 2 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | August 31, 2011 | December 23, 2016 |
| NCT02670616 | Completed | Phase 2 | Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | May 1, 2016 | October 2020 |
| NCT01445535 | Completed | Phase 1 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | January 13, 2009 | October 22, 2020 |
| NCT01451515 | Completed | Phase 2 | NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | May 25, 2012 | May 31, 2022 |
| NCT02617485 | Completed | Phase 3 | MabionCD20 Compared to MabThera in Lymphoma Patients | December 2015 | January 2018 |
| NCT02596971 | Completed | Phase 1/Phase 2 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | December 22, 2015 | May 8, 2020 |
| NCT01490060 | Completed | N/A | Fosaprepitant in Patients Receiving Ifosfamide-based Regimen | May 2012 | March 2016 |
| NCT01523977 | Completed | Phase 1 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | November 2011 | November 2018 |
| NCT01528046 | Completed | Phase 1 | Metformin in Children With Relapsed or Refractory Solid Tumors | September 24, 2012 | February 3, 2020 |
| NCT01542736 | Completed | Phase 2 | Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) | May 2007 | September 2020 |
| NCT01622439 | Completed | Phase 1/Phase 2 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma | June 2012 | March 2018 |
| NCT01679119 | Completed | Phase 2 | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy | October 2013 | March 2022 |
| NCT02529852 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | November 4, 2015 | October 31, 2022 |
| NCT02523976 | Completed | Phase 2 | Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | August 1, 2015 | December 31, 2021 |
| NCT02406092 | Completed | Phase 3 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | October 13, 2015 | June 30, 2021 |
| NCT01760226 | Completed | Early Phase 1 | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies | January 2013 | December 2016 |
| NCT01777152 | Completed | Phase 3 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | January 31, 2013 | October 2, 2020 |
| NCT02398240 | Completed | Phase 2 | Brentuximab for Newly Diagnosed Hodgkin Disease | May 2015 | December 2022 |
| NCT01848132 | Completed | Phase 2 | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. | October 3, 2013 | August 2018 |
| NCT01855750 | Completed | Phase 3 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | September 3, 2013 | April 5, 2019 |
| NCT02348216 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | April 21, 2015 | July 27, 2023 |
| NCT01889069 | Completed | Phase 3 | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) | July 31, 2013 | May 28, 2019 |
| NCT02343536 | Completed | Phase 1 | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | April 29, 2015 | January 29, 2020 |
| NCT01974440 | Completed | Phase 3 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | January 31, 2014 | June 21, 2023 |
| NCT02035137 | Completed | Phase 2 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat | July 2014 | February 26, 2021 |
| NCT02036489 | Completed | Phase 4 | Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | January 2008 | December 1, 2019 |
| NCT02055820 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | November 17, 2013 | June 28, 2019 |
| NCT02285062 | Completed | Phase 3 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma | February 17, 2015 | July 28, 2022 |
| NCT00003389 | Completed | Phase 3 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | June 17, 1999 | May 2016 |
| NCT00026208 | Completed | Phase 2 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | June 2001 | February 13, 2017 |
| NCT00001689 | Completed | Phase 1 | A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | January 1998 | November 2003 |
| NCT00038610 | Completed | Phase 2 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | March 2001 | July 2014 |
| NCT00041132 | Completed | Phase 2 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | September 2002 | June 2011 |
| NCT00051311 | Completed | Phase 2 | Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | January 3, 2003 | September 25, 2014 |
| NCT00054665 | Completed | Phase 2 | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | February 2003 | July 2009 |
| NCT00083551 | Completed | Phase 3 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | August 1998 | August 2014 |
| NCT00085202 | Completed | Phase 3 | Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor | August 2003 | December 31, 2023 |
| NCT00101101 | Completed | Phase 2 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | July 2004 | June 14, 2021 |
| NCT00109837 | Completed | Phase 2 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2005 | November 2014 |
| NCT00115700 | Completed | Phase 3 | Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma | February 2000 | August 2018 |
| NCT00118209 | Completed | Phase 3 | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma | May 2005 | November 15, 2021 |
| NCT00130195 | Completed | Phase 2 | Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | September 2002 | May 2008 |
| NCT04933617 | Completed | Phase 1 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | March 24, 2022 | November 30, 2023 |
| NCT00133991 | Completed | Phase 2 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia | July 2005 | August 2013 |
| NCT00165139 | Completed | Phase 2 | Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | January 1996 | February 2009 |
| NCT00165178 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia in Children | September 2000 | May 2011 |
| NCT00169156 | Completed | Phase 2 | A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma | December 2005 | November 2012 |
| NCT00176462 | Completed | Phase 2 | CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | February 2001 | September 2008 |
| NCT00187122 | Completed | N/A | Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma | March 1993 | June 2004 |
| NCT00193479 | Completed | Phase 2 | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | April 2003 | February 2010 |
| NCT00198978 | Completed | Phase 4 | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 2003 | June 2014 |
| NCT00198991 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) | April 2003 | June 30, 2013 |
| NCT00199004 | Completed | Phase 4 | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab | April 2004 | March 2009 |
| NCT00199017 | Completed | Phase 4 | German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults | April 2004 | |
| NCT00199069 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) | April 1993 | May 2001 |
| NCT00199095 | Completed | Phase 4 | Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia | February 1997 | June 2003 |
| NCT00201695 | Completed | Phase 2 | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | July 2004 | August 2008 |
| NCT04752163 | Completed | Phase 1/Phase 2 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | March 25, 2021 | November 8, 2023 |
| NCT04660799 | Completed | Phase 2 | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) | February 24, 2021 | October 11, 2022 |
| NCT00211185 | Completed | Phase 2 | A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma | March 14, 2004 | December 23, 2009 |
| NCT00217425 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms | September 14, 2006 | March 2014 |
| NCT03991884 | Completed | Phase 1 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | September 24, 2019 | June 28, 2023 |
| NCT00264953 | Completed | Phase 3 | HD11 for Intermediate Stages | May 1998 | |
| NCT00265031 | Completed | Phase 3 | HD12 for Advanced Stages | January 1999 | |
| NCT00267046 | Completed | Phase 2 | Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma | December 2005 | July 2009 |
| NCT00274924 | Completed | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma | September 26, 2006 | March 2019 |
| NCT00284271 | Completed | Phase 2 | Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma | January 2004 | |
| NCT00285389 | Completed | Phase 2 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | February 2002 | December 2008 |
| NCT00290433 | Completed | Phase 2 | Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma | September 2003 | July 2015 |
| NCT00290498 | Completed | Phase 2 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | August 1, 2005 | August 11, 2017 |
| NCT00299182 | Completed | Phase 1/Phase 2 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | March 2006 | April 2012 |
| NCT00313079 | Completed | Phase 1 | Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia | May 2006 | July 2009 |
| NCT03817853 | Completed | Phase 4 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | February 26, 2019 | January 25, 2023 |
| NCT00352027 | Completed | Phase 2 | Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | July 20, 2006 | November 15, 2022 |
| NCT00379574 | Completed | Phase 1/Phase 2 | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | September 2006 | January 2011 |
| NCT00390793 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | September 28, 2006 | February 2, 2024 |
| NCT00410488 | Completed | N/A | Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI) | December 2006 | June 2011 |
| NCT00411541 | Completed | Phase 4 | Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia | April 1995 | January 2004 |
| NCT00433537 | Completed | Phase 2 | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma | May 2007 | June 2013 |
| NCT00440726 | Completed | Phase 1/Phase 2 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | August 4, 2006 | February 26, 2011 |
| NCT02162771 | Completed | Phase 3 | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan | July 14, 2014 | December 29, 2018 |
| NCT02228772 | Completed | Phase 1 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | December 2014 | November 2019 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT05678933 | Enrolling by invitation | Phase 3 | AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH | January 1, 2023 | December 1, 2029 |
| NCT06201507 | Enrolling by invitation | Phase 2 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | October 1, 2022 | December 31, 2025 |
| NCT06425302 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | August 3, 2024 | November 27, 2028 |
| NCT03892330 | Not yet recruiting | Phase 4 | Combination Therapy of Anthracyclines for Children With Nephroblastoma | June 1, 2019 | June 30, 2045 |
| NCT04199026 | Not yet recruiting | Early Phase 1 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | January 31, 2025 | December 31, 2025 |
| NCT04440267 | Not yet recruiting | Phase 2 | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | June 20, 2020 | December 20, 2025 |
| NCT04890093 | Not yet recruiting | Phase 1/Phase 2 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | June 23, 2024 | December 31, 2026 |
| NCT05466175 | Not yet recruiting | Phase 2 | A Study of Olverembatinib in the Treatment of Ph+ ALL | October 1, 2022 | September 30, 2024 |
| NCT05521087 | Not yet recruiting | Phase 1 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | December 26, 2025 | January 29, 2030 |
| NCT05887726 | Not yet recruiting | Phase 2 | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | August 1, 2023 | August 1, 2025 |
| NCT05990985 | Not yet recruiting | N/A | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | September 1, 2023 | August 1, 2026 |
| NCT06124157 | Not yet recruiting | Phase 3 | A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | July 22, 2024 | December 1, 2030 |
| NCT06175702 | Not yet recruiting | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | December 25, 2023 | December 25, 2030 | |
| NCT06207123 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | April 1, 2025 | December 1, 2026 |
| NCT06220032 | Not yet recruiting | Phase 3 | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | May 21, 2024 | December 15, 2028 |
| NCT06249191 | Not yet recruiting | Phase 1/Phase 2 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | May 31, 2024 | April 1, 2027 |
| NCT06289673 | Not yet recruiting | Phase 4 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | July 2024 | May 2039 |
| NCT06313996 | Not yet recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | March 29, 2024 | October 16, 2031 |
| NCT06317662 | Not yet recruiting | Phase 2 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | July 31, 2024 | December 21, 2027 |
| NCT06387121 | Not yet recruiting | Phase 2 | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL | April 15, 2024 | December 31, 2028 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT06401330 | Not yet recruiting | Phase 3 | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | June 12, 2024 | February 13, 2031 |
| NCT05422066 | Recruiting | Phase 2 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | July 26, 2022 | December 31, 2025 |
| NCT01704716 | Recruiting | Phase 3 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | February 2002 | September 2026 |
| NCT02611492 | Recruiting | Phase 3 | A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults | April 2016 | December 2025 |
| NCT02639650 | Recruiting | Phase 3 | Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | March 1, 2016 | March 1, 2026 |
| NCT01371630 | Recruiting | Phase 1/Phase 2 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | August 26, 2011 | December 25, 2025 |
| NCT02797717 | Recruiting | N/A | Treatment for Classical Hodgkin Lymphoma in Children and Adolescents | November 2015 | December 2027 |
| NCT02870907 | Recruiting | Phase 2 | Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) | March 2010 | September 2030 |
| NCT02981628 | Recruiting | Phase 2 | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | June 19, 2017 | March 31, 2026 |
| NCT03206671 | Recruiting | Phase 3 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | August 3, 2017 | August 2024 |
| NCT00887146 | Recruiting | Phase 3 | Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma | September 2009 | October 2025 |
| NCT03286634 | Recruiting | Phase 2 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | April 18, 2017 | March 31, 2033 |
| NCT03359005 | Recruiting | Phase 2 | Irinotecan and Temozolomide for Ewing Sarcoma | February 7, 2018 | February 28, 2025 |
| NCT03571321 | Recruiting | Phase 1 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | May 28, 2019 | September 5, 2027 |
| NCT03643276 | Recruiting | Phase 3 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | July 15, 2018 | July 14, 2028 |
| NCT03755804 | Recruiting | Phase 2 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | December 12, 2018 | July 1, 2028 |
| NCT03758989 | Recruiting | Phase 2 | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | May 8, 2019 | June 1, 2026 |
| NCT03837873 | Recruiting | Phase 2 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | January 21, 2019 | September 1, 2024 |
| NCT06097364 | Recruiting | Phase 3 | A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma | November 14, 2023 | January 24, 2030 |
| NCT03899337 | Recruiting | Phase 2 | A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | July 23, 2019 | May 31, 2027 |
| NCT03943901 | Recruiting | Phase 2 | Split-Dose R-CHOP for Older Adults With DLBCL | February 17, 2021 | May 2026 |
| NCT04043494 | Recruiting | Phase 3 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma | August 23, 2019 | November 22, 2027 |
| NCT04067037 | Recruiting | Phase 2 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | August 26, 2019 | December 31, 2024 |
| NCT04139304 | Recruiting | Early Phase 1 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | May 24, 2021 | August 2027 |
| NCT06356129 | Recruiting | Phase 3 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | June 24, 2024 | November 20, 2029 |
| NCT04216524 | Recruiting | Phase 2 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | May 29, 2020 | December 31, 2026 |
| NCT04221035 | Recruiting | Phase 3 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | November 5, 2019 | November 2032 |
| NCT04322318 | Recruiting | Phase 2 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | October 19, 2020 | July 1, 2027 |
| NCT04388839 | Recruiting | Phase 2 | Evolutionary Therapy for Rhabdomyosarcoma | September 27, 2020 | December 2027 |
| NCT04402073 | Recruiting | Phase 2 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma | November 11, 2022 | March 1, 2030 |
| NCT04423926 | Recruiting | Phase 1/Phase 2 | Lenalidomide in Combination With CHOP in Patients With Untreated PTCL | June 10, 2020 | December 31, 2024 |
| NCT04432714 | Recruiting | Phase 1/Phase 2 | Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement | June 9, 2020 | December 31, 2026 |
| NCT06172296 | Recruiting | Phase 3 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | April 19, 2024 | December 31, 2029 |
| NCT04625907 | Recruiting | Phase 1/Phase 2 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | September 17, 2020 | June 2030 |
| NCT04638790 | Recruiting | Phase 3 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | February 1, 2020 | December 31, 2026 |
| NCT04668365 | Recruiting | Phase 2 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma | December 25, 2020 | December 25, 2025 |
| NCT04747912 | Recruiting | Phase 2 | Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | March 2, 2021 | May 1, 2026 |
| NCT04796012 | Recruiting | Phase 1/Phase 2 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | April 18, 2023 | January 2025 |
| NCT04803201 | Recruiting | Phase 2 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | July 30, 2021 | January 1, 2026 |
| NCT04835870 | Recruiting | Phase 2 | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | April 1, 2021 | October 1, 2025 |
| NCT04884035 | Recruiting | Phase 1 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | September 15, 2021 | February 4, 2026 |
| NCT04922567 | Recruiting | Phase 2 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | April 1, 2021 | December 31, 2026 |
| NCT04947501 | Recruiting | Early Phase 1 | A Study of N9 Chemotherapy in Children With Neuroblastoma | June 22, 2021 | June 22, 2025 |
| NCT04978584 | Recruiting | Phase 2 | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | March 3, 2022 | January 16, 2025 |
| NCT05032183 | Recruiting | Phase 1/Phase 2 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 17, 2022 | July 1, 2025 |
| NCT05200312 | Recruiting | Phase 2 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma | February 1, 2022 | February 1, 2025 |
| NCT05270057 | Recruiting | Phase 1 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | January 26, 2023 | May 2026 |
| NCT05278715 | Recruiting | Phase 2 | Modified CV Regimen in Optic Pathway Glioma | April 13, 2022 | December 31, 2024 |
| NCT05292664 | Recruiting | Phase 1 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | March 29, 2023 | April 2, 2027 |
| NCT05303792 | Recruiting | Phase 2 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | February 27, 2023 | May 2028 |
| NCT05304585 | Recruiting | Phase 3 | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | August 4, 2022 | December 31, 2030 |
| NCT05351346 | Recruiting | Phase 3 | Genotype-guided Treatment in DLBCL | June 1, 2022 | June 1, 2026 |
| NCT05359237 | Recruiting | Vincristine Pharmacokinetics in Infants | November 16, 2022 | July 31, 2024 | |
| NCT05371093 | Recruiting | Phase 3 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | September 12, 2022 | October 2030 |
| NCT05384821 | Recruiting | Phase 1/Phase 2 | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) | September 14, 2022 | October 2028 |
| NCT05389423 | Recruiting | Phase 1 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | June 27, 2023 | June 1, 2032 |
| NCT05453500 | Recruiting | Phase 2 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | March 27, 2023 | September 1, 2030 |
| NCT05455697 | Recruiting | Phase 1/Phase 2 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | January 26, 2023 | July 6, 2026 |
| NCT06191744 | Recruiting | Phase 3 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | February 5, 2024 | May 18, 2037 |
| NCT05476770 | Recruiting | Phase 1 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | November 11, 2022 | November 11, 2027 |
| NCT05504291 | Recruiting | Phase 2 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | November 4, 2022 | December 31, 2026 |
| NCT05535166 | Recruiting | Phase 2 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | December 20, 2022 | July 2035 |
| NCT05578976 | Recruiting | Phase 3 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | February 8, 2023 | December 30, 2029 |
| NCT05594784 | Recruiting | Phase 2 | Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL | October 8, 2022 | March 1, 2025 |
| NCT05600686 | Recruiting | Phase 2 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | May 24, 2023 | February 1, 2028 |
| NCT05605899 | Recruiting | Phase 3 | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | February 10, 2023 | March 2031 |
| NCT05620862 | Recruiting | Phase 1 | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | October 25, 2022 | June 1, 2025 |
| NCT05645718 | Recruiting | Phase 2 | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | July 14, 2023 | December 31, 2029 |
| NCT05660473 | Recruiting | Phase 2 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | October 31, 2022 | December 30, 2027 |
| NCT05844670 | Recruiting | Phase 4 | CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients. | April 20, 2023 | November 1, 2024 |
| NCT05848765 | Recruiting | Phase 2 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | September 4, 2023 | November 30, 2031 |
| NCT06336395 | Recruiting | Phase 2 | Ma-Spore ALL 2020 Study | March 4, 2020 | March 2030 |
| NCT05899621 | Recruiting | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | June 1, 2023 | June 30, 2027 | |
| NCT06023641 | Recruiting | Phase 1/Phase 2 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | March 13, 2024 | October 2037 |
| NCT06045247 | Recruiting | Phase 2 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | January 5, 2024 | July 31, 2030 |
| NCT06091254 | Recruiting | Phase 3 | A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma | December 12, 2023 | April 3, 2029 |
| NCT06091865 | Recruiting | Phase 3 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | December 13, 2023 | September 18, 2028 |
| NCT01837862 | Recruiting | Phase 1/Phase 2 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | October 22, 2013 | April 2025 |
| NCT02449252 | Recruiting | Phase 3 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | October 2015 | October 2025 |
| NCT02449265 | Recruiting | Phase 3 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | October 2015 | October 2025 |
| NCT02449278 | Recruiting | Phase 3 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | October 2015 | October 2025 |
| NCT00324831 | Suspended | Phase 3 | GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | ||
| NCT05382338 | Suspended | Phase 3 | A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | February 20, 2023 | December 20, 2027 |
| NCT02212574 | Terminated | Early Phase 1 | Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma | April 4, 2017 | November 9, 2018 |
| NCT00313053 | Terminated | Phase 1 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | September 2004 | July 2008 |
| NCT00088881 | Terminated | Phase 2 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | December 2004 | March 2011 |
| NCT02359162 | Terminated | Phase 3 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | May 2015 | June 2017 |
| NCT00225173 | Terminated | Phase 2 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | October 2001 | September 2006 |
| NCT00215943 | Terminated | Phase 3 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | June 2003 | August 2012 |
| NCT02404220 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | May 6, 2015 | December 17, 2018 |
| NCT02531308 | Terminated | Phase 2 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | July 2015 | July 2016 |
| NCT02535806 | Terminated | Phase 2 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | July 2015 | May 25, 2017 |
| NCT01659099 | Terminated | Phase 3 | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | September 2012 | December 31, 2017 |
| NCT02568683 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | February 11, 2016 | June 22, 2017 |
| NCT01483690 | Terminated | Phase 1/Phase 2 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | December 2011 | July 31, 2015 |
| NCT01746173 | Terminated | Phase 2 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | July 2013 | October 2014 |
| NCT02626455 | Terminated | Phase 3 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | January 6, 2016 | November 10, 2023 |
| NCT01463852 | Terminated | Early Phase 1 | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) | October 2012 | December 2014 |
| NCT01390584 | Terminated | Phase 2 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | May 24, 2013 | May 18, 2018 |
| NCT02703272 | Terminated | Phase 3 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | July 1, 2016 | June 11, 2021 |
| NCT01370694 | Terminated | Phase 1 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | August 19, 2011 | December 1, 2014 |
| NCT01321008 | Terminated | Phase 1/Phase 2 | Stage I/II Nasal NK Cell Lymphoma | May 2011 | May 2013 |
| NCT01313884 | Terminated | Phase 2 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | May 2011 | July 2014 |
| NCT02855359 | Terminated | Phase 2 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | August 2016 | May 15, 2018 |
| NCT01287741 | Terminated | Phase 3 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | July 26, 2011 | January 31, 2018 |
| NCT01186328 | Terminated | Phase 1 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | August 24, 2010 | January 10, 2012 |
| NCT01014767 | Terminated | Phase 3 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | November 2009 | January 2014 |
| NCT00960063 | Terminated | Phase 1 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | November 11, 2009 | December 22, 2010 |
| NCT00928200 | Terminated | Phase 1 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | April 13, 2009 | June 4, 2010 |
| NCT02419469 | Terminated | Phase 2 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | November 13, 2015 | June 22, 2017 |
| NCT03225924 | Terminated | Phase 1/Phase 2 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | July 26, 2017 | October 18, 2019 |
| NCT02420717 | Terminated | Phase 2 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | July 15, 2015 | January 20, 2021 |
| NCT00841945 | Terminated | Phase 3 | Treatment of Aggressive Localized Lymphoma | April 2005 | February 2017 |
| NCT00809341 | Terminated | Phase 2 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | January 2009 | April 2014 |
| NCT00031590 | Terminated | Phase 2 | Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | April 2001 | May 2011 |
| NCT00632827 | Terminated | Phase 2 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) | July 1, 2008 | June 23, 2016 |
| NCT00135499 | Terminated | Phase 3 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | October 16, 2001 | April 27, 2010 |
| NCT00562965 | Terminated | Phase 3 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | November 2007 | April 2011 |
| NCT00555464 | Terminated | Phase 2 | Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas | November 2007 | December 2012 |
| NCT00500890 | Terminated | Phase 3 | Treatment of Tumors of the Choroid Plexus Epithelium | September 2, 2005 | December 14, 2017 |
| NCT00450385 | Terminated | Phase 2 | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | April 24, 2007 | May 2016 |
| NCT00441168 | Terminated | Phase 2 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | December 2006 | January 2008 |
| NCT00038142 | Terminated | Phase 2 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | November 1997 | March 2016 |
| NCT00361621 | Terminated | Phase 2 | Ph II CHOP+Velcade in Mediastinal LBCL | July 2006 | May 2008 |
| NCT00335140 | Terminated | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | August 23, 2007 | July 2015 |
| NCT03860844 | Terminated | Phase 2 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | August 6, 2019 | May 26, 2023 |
| NCT03864419 | Terminated | Phase 1 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | October 24, 2019 | July 26, 2023 |
| NCT00126191 | Terminated | Phase 2 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | July 2005 | June 2011 |
| NCT00262925 | Terminated | Phase 2 | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | June 2006 | February 2013 |
| NCT00074490 | Terminated | Phase 2 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | January 1, 2004 | August 16, 2017 |
| NCT00250718 | Terminated | Phase 2 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | October 2004 | May 2014 |
| NCT02163356 | Terminated | Phase 1 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma | May 2014 | May 2018 |
| NCT02116959 | Terminated | Phase 1 | Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma | July 23, 2014 | May 25, 2019 |
| NCT02110069 | Terminated | Phase 2 | A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors | June 14, 2017 | October 27, 2020 |
| NCT01925612 | Terminated | Phase 2 | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | August 2013 | May 1, 2017 |
| NCT01887587 | Terminated | Phase 1 | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | June 2013 | February 29, 2016 |
| NCT00060346 | Terminated | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | October 5, 2004 | August 2012 |
| NCT02455245 | Unknown status | Phase 3 | A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma | March 2015 | April 2021 |
| NCT01303887 | Unknown status | Phase 3 | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients | October 2009 | September 2016 |
| NCT03553238 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | February 14, 2016 | August 30, 2020 |
| NCT02894645 | Unknown status | Phase 4 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | October 2008 | |
| NCT03553537 | Unknown status | Phase 3 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | June 2018 | July 2021 |
| NCT02918747 | Unknown status | Phase 2 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | September 2016 | December 2021 |
| NCT02951728 | Unknown status | Phase 1/Phase 2 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma | October 2016 | October 2020 |
| NCT00199186 | Unknown status | Phase 2 | Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | March 2002 | |
| NCT03564704 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | February 14, 2016 | May 30, 2021 |
| NCT01009970 | Unknown status | Phase 2 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | May 2010 | May 2012 |
| NCT04181489 | Unknown status | Phase 2 | Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS | January 1, 2019 | December 30, 2023 |
| NCT03018626 | Unknown status | Phase 3 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | July 27, 2017 | January 2021 |
| NCT02753647 | Unknown status | Phase 2 | Chidamide Plus R-CHOP in Elderly DLBCL | April 2016 | April 2019 |
| NCT02776605 | Unknown status | Phase 2 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | June 2016 | August 2023 |
| NCT01358201 | Unknown status | Phase 4 | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | May 2010 | December 2022 |
| NCT04025593 | Unknown status | Phase 2 | Biomarker Guided Treatment in DLBCL | July 17, 2019 | June 1, 2023 |
| NCT00324467 | Unknown status | Phase 2 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | August 2006 | December 2021 |
| NCT00491946 | Unknown status | Phase 4 | A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer | June 2004 | |
| NCT02858804 | Unknown status | Phase 4 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL | January 2016 | June 2020 |
| NCT05049473 | Unknown status | Phase 2 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | January 2014 | January 2024 |
| NCT03023358 | Unknown status | Phase 3 | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | February 2017 | March 2019 |
| NCT00209222 | Unknown status | Phase 3 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | July 2004 | December 2014 |
| NCT01735747 | Unknown status | Phase 2 | Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma | June 2008 | November 2013 |
| NCT02428751 | Unknown status | Phase 3 | R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | September 2015 | May 2020 |
| NCT03613428 | Unknown status | Phase 1/Phase 2 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | December 1, 2018 | March 30, 2021 |
| NCT03617432 | Unknown status | Phase 2 | Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | August 28, 2018 | September 30, 2022 |
| NCT00131053 | Unknown status | Phase 2 | Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) | September 2002 | September 2011 |
| NCT03853044 | Unknown status | Phase 2 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | December 29, 2018 | December 2022 |
| NCT01468740 | Unknown status | Phase 2 | Prospective Study on HIV-related Hodgkin Lymphoma | March 2004 | July 2012 |
| NCT03952572 | Unknown status | Phase 3 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | May 10, 2019 | April 30, 2023 |
| NCT01719835 | Unknown status | Phase 2 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study | March 2012 | August 2022 |
| NCT02660762 | Unknown status | Phase 2 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | January 2016 | January 2019 |
| NCT01376427 | Unknown status | N/A | Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years | January 2007 | December 2022 |
| NCT00131027 | Unknown status | Phase 3 | High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) | September 2002 | September 2011 |
| NCT00209209 | Unknown status | Phase 3 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL | January 14, 2004 | December 2018 |
| NCT00333008 | Unknown status | Phase 2 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | May 2006 | |
| NCT00980551 | Withdrawn | N/A | Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma | May 2010 | March 2012 |
| NCT06210750 | Withdrawn | Phase 2 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | August 9, 2024 | September 22, 2026 |
| NCT02595242 | Withdrawn | Phase 1 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | June 2015 | June 2017 |
| NCT05934097 | Withdrawn | Phase 1 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | December 2022 | May 2039 |
| NCT04974996 | Withdrawn | Phase 1 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | February 1, 2022 | May 5, 2027 |
| NCT01415765 | Withdrawn | Phase 1/Phase 2 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | July 15, 2011 | January 7, 2014 |
| NCT02228512 | Withdrawn | Phase 1/Phase 2 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | August 15, 2014 | May 5, 2015 |